Mesenchymal stem cells (MSCs) promote functional recoveries in pathological experimental models of the central nervous system and are currently being tested in clinical trials for neurological disorders. However, no studies have examined the various roles of embryonic stem cell derived (ES)-MSCs in eliciting therapeutic effects for Alzheimer’s disease (AD). In the present study, we investigated the neuroprotective effect of ES-MSCs in cellular and animal models of AD, as well as the safety of the intra-arterial administration of ES-MSCs in an AD animal model. ES-MSCs displayed higher cell viability than that of bone marrow (BM)-MSCs in amyloid-β (Aβ)-induced cellular models. Moreover, the efficacy of autophagy induction in ES-MSCs was comparable to that of BM-MSCs; however, intracellular Aβ levels were more significantly reduced in ES-MSCs than in BM-MSCs. In a rat model of AD, ES-MSCs significantly inhibited Aβ-induced cell death in the hippocampus and promoted autophagolysosomal clearance of Aβ, which was concomitantly followed by decreased levels of Aβ in the hippocampus. Furthermore, ES-MSC treatment in Aβ-treated rats featured a higher memory performance than that of rats injected solely with Aβ. Finally, intra-arterial administration of an appropriate cell density of ES-MSCs was safe and free from in situ occlusion or cerebral ischemia. These data support the therapeutic potential of ES-MSCs and clinical applications of the intra-arterial route of ES-MSC administration in AD.
KozlovS, AfoninA, EvsyukovI, BondarenkoA (2017) Alzheimer’s disease: As it was in the beginning. Rev Neurosci28, 825–843.
5.
CummingsJ, LeeG, RitterA, ZhongK (2018) Alzheimer’s disease drug development pipeline: 2018. Alzheimers Dement (N Y)4, 195–214.
6.
BakshD, SongL, TuanRS (2004) Adult mesenchymal stem cells: Characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med8, 301–316.
7.
ChamberlainG, FoxJ, AshtonB, MiddletonJ (2007) Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells25, 2739–2749.
8.
ZilkaN, ZilkovaM, KazmerovaZ, SarisskyM, CigankovaV, NovakM (2011) Mesenchymal stem cells rescue the Alzheimer’s disease cell model from cell death induced by misfolded truncated tau. Neuroscience193, 330–337.
9.
LeeHJ, LeeJK, LeeH, CarterJE, ChangJW, OhW, YangYS, SuhJG, LeeBH, JinHK, BaeJS (2012) Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer’s disease mouse model through modulation of neuroinflammation. Neurobiol Aging33, 588–602.
10.
KimKS, KimHS, ParkJM, KimHW, ParkMK, LeeHS, LimDS, LeeTH, ChoppM, MoonJ (2013) Long-term immunomodulatory effect of amniotic stem cells in an Alzheimer’s disease model. Neurobiol Aging34, 2408–2420.
11.
YunHM, KimHS, ParkKR, ShinJM, KangAR, LeeKI, SongS, KimYB, HanSB, ChungHM, HongJT (2013) Placenta-derived mesenchymal stem cells improve memory dysfunction in an Abeta(1-42)-infused mouse model of Alzheimer’s disease. Cell Death Dis4, e958.
12.
NaaldijkY, JagerC, FabianC, LeovskyC, BluherA, RudolphL, HinzeA, StolzingA (2017) Effect of systemic transplantation of bone marrow-derived mesenchymal stem cells on neuropathology markers in APP/PS1 Alzheimer mice. Neuropathol App Neurobiol43, 299–314.
13.
LeeJK, JinHK, BaeJS (2009) Bone marrow-derived mesenchymal stem cells reduce brain amyloid-beta deposition and accelerate the activation of microglia in an acutely induced Alzheimer’s disease mouse model. Neurosci Lett450, 136–141.
14.
LeeJK, JinHK, BaeJS (2010) Bone marrow-derived mesenchymal stem cells attenuate amyloid beta-induced memory impairment and apoptosis by inhibiting neuronal cell death. Curr Alzheimer Res7, 540–548.
15.
LeeJK, JinHK, EndoS, SchuchmanEH, CarterJE, BaeJS (2010) Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer’s disease mice by modulation of immune responses. Stem Cells28, 329–343.
KretlowJD, JinYQ, LiuW, ZhangWJ, HongTH, ZhouG, BaggettLS, MikosAG, CaoY (2008) Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells. BMC Cell Biol9, 60.
22.
ZaimM, KaramanS, CetinG, IsikS (2012) Donor age and long-term culture affect differentiation and proliferation of human bone marrow mesenchymal stem cells. Ann Hematol91, 1175–1186.
Mohd AliN, BooL, YeapSK, KyH, SatharasingheDA, LiewWC, OngHK, CheongSK, KamarulT (2016) Probable impact of age and hypoxia on proliferation and microRNA expression profile of bone marrow-derived human mesenchymal stem cells. PeerJ4, e1536.
25.
ReindersME, DreyerGJ, BankJR, RoelofsH, HeidtS, RoelenDL, ZandvlietML, HuurmanVA, FibbeWE, van KootenC, ClaasFH, RabelinkTJ, de FijterJW (2015) Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: The Neptune Study. J Transl Med13, 344.
26.
ZhangJ, HuangXW, WangHJ, LiuXY, ZhangT, WangYC, HuDH (2015) The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy. Stem Cell Res Ther6, 234.
27.
LeePH, LeeJE, KimHS, SongSK, LeeHS, NamHS, CheongJW, JeongY, ParkHJ, KimDJ, NamCM, LeeJD, KimHO, SohnYH (2012) A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol72, 32–40.
28.
KimHN, KimDY, OhSH, KimHS, KimKS, LeePH (2017) Feasibility and efficacy of intra-arterial administration of mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy. Stem Cells Transl Med6, 1424–1433.
29.
GadkariR, ZhaoL, TeklemariamT, HantashBM (2014) Human embryonic stem cell derived-mesenchymal stem cells: An alternative mesenchymal stem cell source for regenerative medicine therapy. Regen Med9, 453–465.
30.
HawkinsKE, CorcelliM, DowdingK, RanzoniAM, VlahovaF, HauKL, HunjanA, PeeblesD, GressensP, HagbergH, de CoppiP, HristovaM, GuillotPV (2018) Embryonic stem cell-derived mesenchymal stem cells (MSCs) have a superior neuroprotective capacity over fetal MSCs in the hypoxic-ischemic mouse brain. Stem Cells Transl Med7, 439–449.
31.
YanL, JiangB, NiuYY, WangHX, LiEQ, YanYP, SunHY, DuanYC, ChangSH, ChenGK, JiWZ, XuRH, SiW (2018) Intrathecal delivery of human ESC-derived mesenchymal stem cell spheres promotes recovery of a primate multiple sclerosis model. Cell Death Dis4, 89.
32.
LeeEJ, LeeHN, KangHJ, KimKH, HurJ, ChoHJ, LeeJ, ChungHM, ChoJ, ChoMY, OhSK, MoonSY, ParkYB, KimHS (2010) Novel embryoid body-based method to derive mesenchymal stem cells from human embryonic stem cells. Tissue Eng Part A16, 705–715.
33.
ChuaJY, PendharkarAV, WangN, ChoiR, AndresRH, GaetaX, ZhangJ, MoseleyME, GuzmanR (2011) Intra-arterial injection of neural stem cells using a microneedle technique does not cause microembolic strokes. J Cereb Blood Flow Metab31, 1263–1271.
34.
PuzzoD, LeeL, PalmeriA, CalabreseG, ArancioO (2014) Behavioral assays with mouse models of Alzheimer’s disease: Practical considerations and guidelines. Biochem Pharmacol88, 450–467.
35.
FaesC, AertsM, GeysH, De SchaepdrijverL (2010) Modeling spatial learning in rats based on Morris water maze experiments. Pharm Stat9, 10–20.
36.
VorheesCV, WilliamsMT (2006) Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat Protoc1, 848–858.
37.
BagyinszkyE, GiauVV, ShimK, SukK, AnSSA, KimS (2017) Role of inflammatory molecules in the Alzheimer’s disease progression and diagnosis. J Neurol Sci376, 242–254.
38.
UddinMS, Al MamunA, LabuZK, Hidalgo-LanussaO, BarretoGE, AshrafGM (2019) Autophagic dysfunction in Alzheimer’s disease: Cellular and molecular mechanistic approaches to halt Alzheimer’s pathogenesis. J Cell Physiol234, 8094–8112.
39.
QuerfurthHW, LaFerlaFM (2010) Alzheimer’s disease. N Engl J Med362, 329–344.
40.
LevineB, KroemerG (2008) Autophagy in the pathogenesis of disease. Cell132, 27–42.
LaiAY, McLaurinJ (2012) Inhibition of amyloid-beta peptide aggregation rescues the autophagic deficits in the TgCRND8 mouse model of Alzheimer disease. Biochim Biophys Acta1822, 1629–1637.
43.
ParrC, CarzanigaR, GentlemanSM, Van LeuvenF, WalterJ, SastreM (2012) Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-beta precursor protein. Mol Cell Biol32, 4410–4418.
44.
WalczakP, ZhangJ, GiladAA, KedziorekDA, Ruiz-CabelloJ, YoungRG, PittengerMF, Van ZijlPCM, HuangJ, BulteJWM (2008) Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke39, 1569–1574.
45.
MitkariB, KerkelaE, NystedtJ, KorhonenM, MikkonenV, HuhtalaT, JolkkonenJ (2013) Intra-arterial infusion of human bone marrow-derived mesenchymal stem cells results in transient localization in the brain after cerebral ischemia in rats. Exp Neurol239, 158–162.
46.
WangLQ, LinZZ, ZhangHX, ShaoB, XiaoL, JiangHG, ZhugeQC, XieLK, WangB, SuDM, JinKL (2014) Timing and dose regimens of marrow mesenchymal stem cell transplantation affect the outcomes and neuroinflammatory response after ischemic stroke. CNS Neurosci Ther20, 317–326.
47.
KimJY, KimDH, KimDS, KimJH, JeongSY, JeonHB, LeeEH, YangYS, OhW, ChangJW (2010) Galectin-3 secreted by human umbilical cord blood-derived mesenchymal stem cells reduces amyloid-beta42 neurotoxicity in vitro. FEBS Lett584, 3601–3608.
LeeJK, SchuchmanEH, JinHK, BaeJS (2012) Soluble CCL5 derived from bone marrow-derived mesenchymal stem cells and activated by amyloid beta ameliorates Alzheimer’s disease in mice by recruiting bone marrow-induced microglia immune responses. Stem Cells30, 1544–1555.
